全球生物科技的联盟条件与契约:2017年～2022年

本报告提供全球生物科技的联盟条件与契约的相关调查，彙整交易趋势与策略，交易条件，联盟企业简介等资讯。

目录

摘要整理

第1章 简介

第2章 生物科技的交易趋势

• 简介
• 多年的生物科技的联盟
• 最活跃的生物科技的交易业者
• 生物科技的联盟，各交易类型
• 生物科技的联盟，各治疗领域
• 生物科技的联盟，各技术类型
• 生物科技的联盟的交易条件

第3章 生物科技的主要交易

第4章 最活跃的生物科技的交易业者

• 简介
• 最活跃的生物科技的交易业者
• 最活跃的生物科技联盟企业简介

第5章 生物科技的契约交易名录

第6章 生物科技的交易，各技术类型

附录

关于Wildwood Ventures

Global Biotech Partnering Terms and Agreements 2018 to 2023 report provides a detailed understanding and analysis of how and why companies enter biotech partnering deals

Global Biotech Partnering Terms and Agreements 2018 to 2023 report provides a detailed understanding and analysis of how and why companies enter biotech partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest biotech agreements announced in the life sciences since 2018.

The report takes the reader through a comprehensive review biotech deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering biotech partnering deals.

The report presents financial deal term values for biotech deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the biotech partnering field; both the leading deal values and most active biotech dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 6,800 online deal records of actual biotech deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of biotech dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in biotech dealmaking since 2018, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading biotech deals since 2018. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in biotech dealmaking with a brief summary followed by a comprehensive listing of biotech deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of biotech partnering deals signed and announced since Jan 2018, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of biotech partnering deals signed and announced since Jan 2018. The chapter is organized by specific technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by biotech partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in biotech partnering and dealmaking since 2018.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of biotech technologies and products.

Key benefits

Global Biotech Partnering Terms and Agreements 2018 to 2023 provides the reader with the following key benefits:

• In-depth understanding of biotech deal trends since 2018
• Access to headline, upfront, milestone and royalty data
• Detailed access to actual biotech contracts entered into by leading biopharma companies
• Identify most active biotech dealmakers since 2018
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

• Global Biotech Partnering Terms and Agreements 2018 to 2023 is intended to provide the reader with an in-depth understanding and access to biotech trends and structure of deals entered into by leading companies worldwide.

Biotech Partnering Terms and Agreements includes:

• Trends in biotech dealmaking in the biopharma industry since 2018
• Access to headline, upfront, milestone and royalty data
• Access to biotech contract documents
• Leading biotech deals by value since 2018
• Most active biotech dealmakers since 2018

In Global Biotech Partnering Terms and Agreements 2018 to 2023, the available deals are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy target
• Technology type
• Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
• The Global Biotech Partnering Terms and Agreements 2018 to 2023 report provides comprehensive access to available deals and contract documents for over 6,800 biotech deals.

Analyzing actual contract agreements allows assessment of the following:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Biotech Partnering Terms and Agreements 2018-2023 provides the reader with the following key benefits:

• In-depth understanding of biotech deal trends since 2018
• Access to headline, upfront, milestone and royalty data
• Detailed access to actual biotech contracts entered into by leading biopharma companies
• Identify most active biotech dealmakers since 2018
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in biotech dealmaking

• 2.1. Introduction
• 2.2. Biotech partnering over the years
• 2.3. Most active biotech dealmakers
• 2.4. Biotech partnering by deal type
• 2.5. Biotech partnering by therapy area
• 2.6. Biotech partnering by technology type
• 2.7. Deal terms for biotech partnering
  • 2.7.1 Biotech partnering headline values
  • 2.7.2 Biotech deal upfront payments
  • 2.7.3 Biotech deal milestone payments
  • 2.7.4 Biotech royalty rates

Chapter 3 - Leading biotech deals

• 3.1. Introduction
• 3.2. Top biotech deals by value

Chapter 4 - Most active biotech dealmakers

• 4.1. Introduction
• 4.2. Most active biotech dealmakers
• 4.3. Most active biotech partnering company profiles

Chapter 5 - Biotech contracts dealmaking directory

• 5.1. Introduction
• 5.2. Biotech contracts dealmaking directory

Chapter 6 - Biotech dealmaking by technology type

Appendices

• Appendix 1 - Biotech deals by company A-Z
• Appendix 2 - Biotech deals by stage of development
• Appendix 3 - Biotech deals by deal type
• Appendix 4 - Biotech deals by therapy area
• Appendix 5 - Deal type definitions
• Appendix 6 - Further reading

About Wildwood Ventures

• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Biotech partnering since 2018
• Figure 2: Active biotech dealmaking activity- 2018 to 2023
• Figure 3: Biotech partnering by deal type since 2018
• Figure 4: Biotech partnering by disease type since 2018
• Figure 5: Biotech partnering by technology type since 2018
• Figure 6: Biotech deals with a headline value
• Figure 7: Biotech deals with an upfront value
• Figure 8: Biotech deals with a milestone value
• Figure 9: Biotech deals with a royalty rate value
• Figure 10: Top biotech deals by value since 2018
• Figure 11: Most active biotech dealmakers 2018 to 2023